Finally, nude mice bearing ERMS tumors derived from both cell lines were treated with Crizotinib, a well-tolerated dual Met and ALK inhibitor, approved for the treatment of patients with metastatic ALK-positive NSCLC (Rodig and Shapiro, 2010). The gene discussed is ALK; the disease is non-small cell lung carcinoma.